- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Arthritis Research & Therapy 19 (2017).
- Schlagwort
-
-
Hautkrankheit
Dermatologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2017
- Urheber
-
Moritz, Falk
Schniering, Janine
Distler, Jörg H. W.
Gay, Renate E.
Gay, Steffen
Distler, Oliver
Maurer, Britta
- URN
-
urn:nbn:de:bvb:29-opus4-85430
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Moritz, Falk
- Schniering, Janine
- Distler, Jörg H. W.
- Gay, Renate E.
- Gay, Steffen
- Distler, Oliver
- Maurer, Britta
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2017
Ähnliche Objekte (12)
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
Vitamin D receptor regulates TGF-β signalling in systemic sclerosis
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis
Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
Vitamin D receptor regulates TGF-β signalling in systemic sclerosis
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis
Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
Vitamin D receptor regulates TGF-β signalling in systemic sclerosis
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis
Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease